Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daraxonrasib - REVOLUTION Medicines

Next Previous
Drug Profile

Daraxonrasib - REVOLUTION Medicines

Alternative Names: RAS(ON) inhibitor- REVOLUTION Medicines; Ras-IN-2; RASMULTI(ON) Inhibitor - REVOLUTION Medicines; RMC-6236

Latest Information Update: 17 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator REVOLUTION Medicines
  • Developer Kura Oncology; REVOLUTION Medicines
  • Class Amides; Antineoplastics; Cyclopropanes; Heterocyclic compounds with 4 or more rings; Indoles; Ketones; Methyl ethers; Piperazines; Pyridazines; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Adenocarcinoma; Non-small cell lung cancer
  • Phase I/II Pancreatic cancer
  • Phase I Solid tumours
  • No development reported Colorectal cancer

Most Recent Events

  • 05 Nov 2025 Phase-III clinical trials in Adenocarcinoma (Adjuvant therapy, Second-line therapy or greater) in USA (PO, Tablet) (NCT07252232)
  • 27 Oct 2025 Daraxonrasib receives Orphan Drug status for Pancreatic cancer in USA
  • 16 Oct 2025 US FDA grants non-transferrable voucher to Daraxonrasib under Commissioner's National Priority Voucher (CNPV) pilot program

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top